Cargando…
Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte Count
BACKGROUND: Data on SARS-CoV-2 vaccine immunogenicity in PLWH are currently limited. Aim of the study was to investigate immunogenicity according to current CD4 T-cell count METHODS: PLWH on ART attending a SARS-CoV-2 vaccination program, were included in a prospective immunogenicity evaluation afte...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047161/ https://www.ncbi.nlm.nih.gov/pubmed/35366316 http://dx.doi.org/10.1093/cid/ciac238 |
_version_ | 1784695672343101440 |
---|---|
author | Antinori, Andrea Cicalini, Stefania Meschi, Silvia Bordoni, Veronica Lorenzini, Patrizia Vergori, Alessandra Lanini, Simone De Pascale, Lidya Matusali, Giulia Mariotti, Davide Cozzi Lepri, Alessandro Gallì, Paola Pinnetti, Carmela Gagliardini, Roberta Mazzotta, Valentina Mastrorosa, Ilaria Grisetti, Susanna Colavita, Francesca Cimini, Eleonora Grilli, Elisabetta Bellagamba, Rita Lapa, Daniele Sacchi, Alessandra Marani, Alessandra Cerini, Carlo Candela, Caterina Fusto, Marisa Puro, Vincenzo Castilletti, Concetta Agrati, Chiara Girardi, Enrico Vaia, Francesco |
author_facet | Antinori, Andrea Cicalini, Stefania Meschi, Silvia Bordoni, Veronica Lorenzini, Patrizia Vergori, Alessandra Lanini, Simone De Pascale, Lidya Matusali, Giulia Mariotti, Davide Cozzi Lepri, Alessandro Gallì, Paola Pinnetti, Carmela Gagliardini, Roberta Mazzotta, Valentina Mastrorosa, Ilaria Grisetti, Susanna Colavita, Francesca Cimini, Eleonora Grilli, Elisabetta Bellagamba, Rita Lapa, Daniele Sacchi, Alessandra Marani, Alessandra Cerini, Carlo Candela, Caterina Fusto, Marisa Puro, Vincenzo Castilletti, Concetta Agrati, Chiara Girardi, Enrico Vaia, Francesco |
author_sort | Antinori, Andrea |
collection | PubMed |
description | BACKGROUND: Data on SARS-CoV-2 vaccine immunogenicity in PLWH are currently limited. Aim of the study was to investigate immunogenicity according to current CD4 T-cell count METHODS: PLWH on ART attending a SARS-CoV-2 vaccination program, were included in a prospective immunogenicity evaluation after receiving BNT162b2 or mRNA-1273. Participants were stratified by current CD4 T-cell count (poor CD4 recovery, PCDR: <200/mm(3); intermediate CD4 recovery, ICDR: 200–500/mm(3); high CD4 recovery, HCDR: >500/mm(3)). RBD-binding IgG, SARS-CoV-2 neutralizing antibodies (nAbs) and IFN-γ release were measured. As control group, HIV-negative healthcare workers (HCWs) were used FINDINGS: Among 166 PLWH, after 1 month from the booster dose, detectable RBD-binding IgG were elicited in 86.7% of PCDR, 100% of ICDR, 98.7% of HCDR, and a neutralizing titre ≥1:10 elicited in 70.0%, 88.2%, and 93.1%, respectively. Compared to HCDR, all immune response parameters were significantly lower in PCDR. After adjusting for confounders, current CD4 T-cell <200/mm3 significantly predicted a poor magnitude of anti-RDB, nAbs and IFN-γ response. As compared with HCWs, PCDR elicited a consistently reduced immunogenicity for all parameters, ICDR only a reduced RBD-binding antibody response, whereas HCDR elicited a comparable immune response for all parameters CONCLUSION: Humoral and cell-mediated immune response against SARS-CoV-2 were elicited in most of PLWH, albeit significantly poorer in those with CD4 T-cell <200/mm(3) versus those with >500 cell/mm(3) and HIV-negative controls. A lower RBD-binding antibody response than HCWs was also observed in PLWH with CD4 T-cell 200–500/mm(3), whereas immune response elicited in PLWH with a CD4 T-cell >500/mm(3) was comparable to HIV-negative population |
format | Online Article Text |
id | pubmed-9047161 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-90471612022-04-28 Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte Count Antinori, Andrea Cicalini, Stefania Meschi, Silvia Bordoni, Veronica Lorenzini, Patrizia Vergori, Alessandra Lanini, Simone De Pascale, Lidya Matusali, Giulia Mariotti, Davide Cozzi Lepri, Alessandro Gallì, Paola Pinnetti, Carmela Gagliardini, Roberta Mazzotta, Valentina Mastrorosa, Ilaria Grisetti, Susanna Colavita, Francesca Cimini, Eleonora Grilli, Elisabetta Bellagamba, Rita Lapa, Daniele Sacchi, Alessandra Marani, Alessandra Cerini, Carlo Candela, Caterina Fusto, Marisa Puro, Vincenzo Castilletti, Concetta Agrati, Chiara Girardi, Enrico Vaia, Francesco Clin Infect Dis Major Article BACKGROUND: Data on SARS-CoV-2 vaccine immunogenicity in PLWH are currently limited. Aim of the study was to investigate immunogenicity according to current CD4 T-cell count METHODS: PLWH on ART attending a SARS-CoV-2 vaccination program, were included in a prospective immunogenicity evaluation after receiving BNT162b2 or mRNA-1273. Participants were stratified by current CD4 T-cell count (poor CD4 recovery, PCDR: <200/mm(3); intermediate CD4 recovery, ICDR: 200–500/mm(3); high CD4 recovery, HCDR: >500/mm(3)). RBD-binding IgG, SARS-CoV-2 neutralizing antibodies (nAbs) and IFN-γ release were measured. As control group, HIV-negative healthcare workers (HCWs) were used FINDINGS: Among 166 PLWH, after 1 month from the booster dose, detectable RBD-binding IgG were elicited in 86.7% of PCDR, 100% of ICDR, 98.7% of HCDR, and a neutralizing titre ≥1:10 elicited in 70.0%, 88.2%, and 93.1%, respectively. Compared to HCDR, all immune response parameters were significantly lower in PCDR. After adjusting for confounders, current CD4 T-cell <200/mm3 significantly predicted a poor magnitude of anti-RDB, nAbs and IFN-γ response. As compared with HCWs, PCDR elicited a consistently reduced immunogenicity for all parameters, ICDR only a reduced RBD-binding antibody response, whereas HCDR elicited a comparable immune response for all parameters CONCLUSION: Humoral and cell-mediated immune response against SARS-CoV-2 were elicited in most of PLWH, albeit significantly poorer in those with CD4 T-cell <200/mm(3) versus those with >500 cell/mm(3) and HIV-negative controls. A lower RBD-binding antibody response than HCWs was also observed in PLWH with CD4 T-cell 200–500/mm(3), whereas immune response elicited in PLWH with a CD4 T-cell >500/mm(3) was comparable to HIV-negative population Oxford University Press 2022-04-02 /pmc/articles/PMC9047161/ /pubmed/35366316 http://dx.doi.org/10.1093/cid/ciac238 Text en © The Author(s) 2022. Published by Oxford University Press for the Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Major Article Antinori, Andrea Cicalini, Stefania Meschi, Silvia Bordoni, Veronica Lorenzini, Patrizia Vergori, Alessandra Lanini, Simone De Pascale, Lidya Matusali, Giulia Mariotti, Davide Cozzi Lepri, Alessandro Gallì, Paola Pinnetti, Carmela Gagliardini, Roberta Mazzotta, Valentina Mastrorosa, Ilaria Grisetti, Susanna Colavita, Francesca Cimini, Eleonora Grilli, Elisabetta Bellagamba, Rita Lapa, Daniele Sacchi, Alessandra Marani, Alessandra Cerini, Carlo Candela, Caterina Fusto, Marisa Puro, Vincenzo Castilletti, Concetta Agrati, Chiara Girardi, Enrico Vaia, Francesco Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte Count |
title | Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte Count |
title_full | Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte Count |
title_fullStr | Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte Count |
title_full_unstemmed | Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte Count |
title_short | Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte Count |
title_sort | humoral and cellular immune response elicited by mrna vaccination against severe acute respiratory syndrome coronavirus 2 (sars-cov-2) in people living with human immunodeficiency virus receiving antiretroviral therapy based on current cd4 t-lymphocyte count |
topic | Major Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047161/ https://www.ncbi.nlm.nih.gov/pubmed/35366316 http://dx.doi.org/10.1093/cid/ciac238 |
work_keys_str_mv | AT antinoriandrea humoralandcellularimmuneresponseelicitedbymrnavaccinationagainstsevereacuterespiratorysyndromecoronavirus2sarscov2inpeoplelivingwithhumanimmunodeficiencyvirusreceivingantiretroviraltherapybasedoncurrentcd4tlymphocytecount AT cicalinistefania humoralandcellularimmuneresponseelicitedbymrnavaccinationagainstsevereacuterespiratorysyndromecoronavirus2sarscov2inpeoplelivingwithhumanimmunodeficiencyvirusreceivingantiretroviraltherapybasedoncurrentcd4tlymphocytecount AT meschisilvia humoralandcellularimmuneresponseelicitedbymrnavaccinationagainstsevereacuterespiratorysyndromecoronavirus2sarscov2inpeoplelivingwithhumanimmunodeficiencyvirusreceivingantiretroviraltherapybasedoncurrentcd4tlymphocytecount AT bordoniveronica humoralandcellularimmuneresponseelicitedbymrnavaccinationagainstsevereacuterespiratorysyndromecoronavirus2sarscov2inpeoplelivingwithhumanimmunodeficiencyvirusreceivingantiretroviraltherapybasedoncurrentcd4tlymphocytecount AT lorenzinipatrizia humoralandcellularimmuneresponseelicitedbymrnavaccinationagainstsevereacuterespiratorysyndromecoronavirus2sarscov2inpeoplelivingwithhumanimmunodeficiencyvirusreceivingantiretroviraltherapybasedoncurrentcd4tlymphocytecount AT vergorialessandra humoralandcellularimmuneresponseelicitedbymrnavaccinationagainstsevereacuterespiratorysyndromecoronavirus2sarscov2inpeoplelivingwithhumanimmunodeficiencyvirusreceivingantiretroviraltherapybasedoncurrentcd4tlymphocytecount AT laninisimone humoralandcellularimmuneresponseelicitedbymrnavaccinationagainstsevereacuterespiratorysyndromecoronavirus2sarscov2inpeoplelivingwithhumanimmunodeficiencyvirusreceivingantiretroviraltherapybasedoncurrentcd4tlymphocytecount AT depascalelidya humoralandcellularimmuneresponseelicitedbymrnavaccinationagainstsevereacuterespiratorysyndromecoronavirus2sarscov2inpeoplelivingwithhumanimmunodeficiencyvirusreceivingantiretroviraltherapybasedoncurrentcd4tlymphocytecount AT matusaligiulia humoralandcellularimmuneresponseelicitedbymrnavaccinationagainstsevereacuterespiratorysyndromecoronavirus2sarscov2inpeoplelivingwithhumanimmunodeficiencyvirusreceivingantiretroviraltherapybasedoncurrentcd4tlymphocytecount AT mariottidavide humoralandcellularimmuneresponseelicitedbymrnavaccinationagainstsevereacuterespiratorysyndromecoronavirus2sarscov2inpeoplelivingwithhumanimmunodeficiencyvirusreceivingantiretroviraltherapybasedoncurrentcd4tlymphocytecount AT cozzileprialessandro humoralandcellularimmuneresponseelicitedbymrnavaccinationagainstsevereacuterespiratorysyndromecoronavirus2sarscov2inpeoplelivingwithhumanimmunodeficiencyvirusreceivingantiretroviraltherapybasedoncurrentcd4tlymphocytecount AT gallipaola humoralandcellularimmuneresponseelicitedbymrnavaccinationagainstsevereacuterespiratorysyndromecoronavirus2sarscov2inpeoplelivingwithhumanimmunodeficiencyvirusreceivingantiretroviraltherapybasedoncurrentcd4tlymphocytecount AT pinnetticarmela humoralandcellularimmuneresponseelicitedbymrnavaccinationagainstsevereacuterespiratorysyndromecoronavirus2sarscov2inpeoplelivingwithhumanimmunodeficiencyvirusreceivingantiretroviraltherapybasedoncurrentcd4tlymphocytecount AT gagliardiniroberta humoralandcellularimmuneresponseelicitedbymrnavaccinationagainstsevereacuterespiratorysyndromecoronavirus2sarscov2inpeoplelivingwithhumanimmunodeficiencyvirusreceivingantiretroviraltherapybasedoncurrentcd4tlymphocytecount AT mazzottavalentina humoralandcellularimmuneresponseelicitedbymrnavaccinationagainstsevereacuterespiratorysyndromecoronavirus2sarscov2inpeoplelivingwithhumanimmunodeficiencyvirusreceivingantiretroviraltherapybasedoncurrentcd4tlymphocytecount AT mastrorosailaria humoralandcellularimmuneresponseelicitedbymrnavaccinationagainstsevereacuterespiratorysyndromecoronavirus2sarscov2inpeoplelivingwithhumanimmunodeficiencyvirusreceivingantiretroviraltherapybasedoncurrentcd4tlymphocytecount AT grisettisusanna humoralandcellularimmuneresponseelicitedbymrnavaccinationagainstsevereacuterespiratorysyndromecoronavirus2sarscov2inpeoplelivingwithhumanimmunodeficiencyvirusreceivingantiretroviraltherapybasedoncurrentcd4tlymphocytecount AT colavitafrancesca humoralandcellularimmuneresponseelicitedbymrnavaccinationagainstsevereacuterespiratorysyndromecoronavirus2sarscov2inpeoplelivingwithhumanimmunodeficiencyvirusreceivingantiretroviraltherapybasedoncurrentcd4tlymphocytecount AT ciminieleonora humoralandcellularimmuneresponseelicitedbymrnavaccinationagainstsevereacuterespiratorysyndromecoronavirus2sarscov2inpeoplelivingwithhumanimmunodeficiencyvirusreceivingantiretroviraltherapybasedoncurrentcd4tlymphocytecount AT grillielisabetta humoralandcellularimmuneresponseelicitedbymrnavaccinationagainstsevereacuterespiratorysyndromecoronavirus2sarscov2inpeoplelivingwithhumanimmunodeficiencyvirusreceivingantiretroviraltherapybasedoncurrentcd4tlymphocytecount AT bellagambarita humoralandcellularimmuneresponseelicitedbymrnavaccinationagainstsevereacuterespiratorysyndromecoronavirus2sarscov2inpeoplelivingwithhumanimmunodeficiencyvirusreceivingantiretroviraltherapybasedoncurrentcd4tlymphocytecount AT lapadaniele humoralandcellularimmuneresponseelicitedbymrnavaccinationagainstsevereacuterespiratorysyndromecoronavirus2sarscov2inpeoplelivingwithhumanimmunodeficiencyvirusreceivingantiretroviraltherapybasedoncurrentcd4tlymphocytecount AT sacchialessandra humoralandcellularimmuneresponseelicitedbymrnavaccinationagainstsevereacuterespiratorysyndromecoronavirus2sarscov2inpeoplelivingwithhumanimmunodeficiencyvirusreceivingantiretroviraltherapybasedoncurrentcd4tlymphocytecount AT maranialessandra humoralandcellularimmuneresponseelicitedbymrnavaccinationagainstsevereacuterespiratorysyndromecoronavirus2sarscov2inpeoplelivingwithhumanimmunodeficiencyvirusreceivingantiretroviraltherapybasedoncurrentcd4tlymphocytecount AT cerinicarlo humoralandcellularimmuneresponseelicitedbymrnavaccinationagainstsevereacuterespiratorysyndromecoronavirus2sarscov2inpeoplelivingwithhumanimmunodeficiencyvirusreceivingantiretroviraltherapybasedoncurrentcd4tlymphocytecount AT candelacaterina humoralandcellularimmuneresponseelicitedbymrnavaccinationagainstsevereacuterespiratorysyndromecoronavirus2sarscov2inpeoplelivingwithhumanimmunodeficiencyvirusreceivingantiretroviraltherapybasedoncurrentcd4tlymphocytecount AT fustomarisa humoralandcellularimmuneresponseelicitedbymrnavaccinationagainstsevereacuterespiratorysyndromecoronavirus2sarscov2inpeoplelivingwithhumanimmunodeficiencyvirusreceivingantiretroviraltherapybasedoncurrentcd4tlymphocytecount AT purovincenzo humoralandcellularimmuneresponseelicitedbymrnavaccinationagainstsevereacuterespiratorysyndromecoronavirus2sarscov2inpeoplelivingwithhumanimmunodeficiencyvirusreceivingantiretroviraltherapybasedoncurrentcd4tlymphocytecount AT castilletticoncetta humoralandcellularimmuneresponseelicitedbymrnavaccinationagainstsevereacuterespiratorysyndromecoronavirus2sarscov2inpeoplelivingwithhumanimmunodeficiencyvirusreceivingantiretroviraltherapybasedoncurrentcd4tlymphocytecount AT agratichiara humoralandcellularimmuneresponseelicitedbymrnavaccinationagainstsevereacuterespiratorysyndromecoronavirus2sarscov2inpeoplelivingwithhumanimmunodeficiencyvirusreceivingantiretroviraltherapybasedoncurrentcd4tlymphocytecount AT girardienrico humoralandcellularimmuneresponseelicitedbymrnavaccinationagainstsevereacuterespiratorysyndromecoronavirus2sarscov2inpeoplelivingwithhumanimmunodeficiencyvirusreceivingantiretroviraltherapybasedoncurrentcd4tlymphocytecount AT vaiafrancesco humoralandcellularimmuneresponseelicitedbymrnavaccinationagainstsevereacuterespiratorysyndromecoronavirus2sarscov2inpeoplelivingwithhumanimmunodeficiencyvirusreceivingantiretroviraltherapybasedoncurrentcd4tlymphocytecount AT humoralandcellularimmuneresponseelicitedbymrnavaccinationagainstsevereacuterespiratorysyndromecoronavirus2sarscov2inpeoplelivingwithhumanimmunodeficiencyvirusreceivingantiretroviraltherapybasedoncurrentcd4tlymphocytecount |